Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients : vimarsana.com

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

Related Keywords

Philadelphia , Pennsylvania , United States , American , Brentl Wood , Susanm Obrien , Anjalis Advani , Aaront Gerds , Jeraldp Radich , Mark Litzow , Janel Liesveld , Matthew Wieduwilt , Anna Moseley , Harryp Erba , Los Angeles , Deepa Jeyakumar , George Yaghmour , Ceciliacs Yeung , Kristen Odwyer , Ehabl Atallah , Megan Othus , Elad Sharon , Uc Irvine Medical Center , Wilmot Cancer Institute , Cancer Research Network , Cleveland Clinic Cancer Institute , National Cancer Institute , Data Management Center , University Of Washington , Amgen Inc , Dana Farber Cancer Institute , University Of Oklahoma , National Clinical Trials Network , Cancer Therapy Evaluation Program , American Society Of Hematology , University Of Rochester , Swog Cancer Research Network , National Institutes Of Health , Bristol Myers Squibb , Memorial Sloan Kettering Cancer Center , College Of Wisconsin , Norris Comprehensive Cancer Center , Duke University Medical Center , Development Agreements , Fred Hutchinson Cancer Center , American Society , Annual Meeting , San Diego , Kristeno Dwyer , Research Network , National Institutes , Myers Squibb , Cooperative Research , Hospital Los Angeles , Jae Park , California San Diego Moores Cancer Center , Medical Center , Comprehensive Cancer Center , Medical College , Mayo Clinic , Therapy Evaluation Program , Duke University Medical , Chemotherapy , Mh , Cute Lymphoblastic Leukemia , Ancer , Hromosome , Linical Trial , Dasatinib , Ematology , Inase , Eukemia , Rednisone , Esearch , Yrosine ,